


Harnessing the Natural Killer Cells for Potent Anticancer Effect



Highly Accomplished Team

To govern and execute on Sauvie's mission



John Canan
Chairman



Scott Oehrlein
Board Director



Ken Suh
CEO, Exec Board Dir.



Brian E. Jahns
C. Operating Officer



Audrey Haukioja
C. Dev. Officer



Dr. Bob Uger
Scientific Advisor



Dr. Albert Agro
Scientific Advisor

Combined +150 years of experience
Multiple start-ups and exits
Private and public company executive leadership
Oncology commercialization and development

Rituxan
Rituximab

Herceptin
trastuzumab
21 mg/mL INJECTION FOR INTRAVENOUS USE

PERJETA
pertuzumab
420 mg INJECTION FOR INTRAVENOUS USE

**>\$40
Billion***
Peak Cumulative
Global Revenue

AFINITOR
(everolimus) tablets

AVASTIN
bevacizumab
100 MG/4 ML INJECTION FOR IV USE

KEYTRUDA
(pembrolizumab) Injection 100 mg

GARDASIL.9
Human Papillomavirus
9-valent Vaccine, Recombinant

Sandostatin LAR Depot
(octreotide acetate) for injectable suspension
10mg · 20mg · 30mg

Patients Still Suffering with HER2+ Tumors

Bi-specific engager initiates a potent anti-cancer process




Patients Still Suffering

~70%
recurrence
in ovarian
cancer


~30%
recurrence
in breast
cancer

33% 5-yr
relative
survival rate
in gastric
cancer*

BiKE binds to NK cells
through CD16a



>1000-fold more potent
than trastuzumab



In vitro study result

BiKE Addresses Large Markets

Potential to be used alone or in combination with leading products



BiKE's lead focus is HER2+ tumors (breast, gastric, ovarian, endometrial, pancreatic)

Breast and gastric cancers

**Herceptin
(trastuzumab)
>\$7 billion
annually**



Breast and gastric cancers in
combination w/ trastuzumab

**Perjeta
(pertuzumab)
>\$4 billion
annually**



10 oncology indications

**Keytruda
(pembrolizumab)
>\$20 billion
annually**



Seed Capital to Advance Program

Tranches to build non-GLP in vivo data in 2023



**Tranche 1:
\$600K**

Immediate

**Tranche 2:
\$800K**

Q3

Potential tax credit eligibility for early investors:

1. NJ Angel Investor Tax Credit Program (regardless of residency in or out of NJ or U.S.) and up to 20% of investment amount within tax year
2. QSBS (Federal program on future capital gains)

Ken Suh
CEO
ksuh@sauvieinc.com

Thank you



www.sauvieinc.com